TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06198764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistimethate sodium for injection
Description: Colistimethate Sodium for Injection is the Prodrug of Polymyxin E, which is hydrolyzed into Polymyxin E after entering the human body to play a bactericidal role.Polymyxin selectively acts on gram-negative aerobic bacteria with hydrophobic outer membrane, leading to cell death by destroying the cell membrane.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem for Injection
Description: Meropenem is a broad-spectrum carbapenem antibiotic that inhibits the synthesis of bacterial cell walls by penetrating the cell wall and reaching its target, the penicillin-binding protein, to ultimately produce antibacterial effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem for Injection
Description: Meropenem is a broad-spectrum carbapenem antibiotic that inhibits the synthesis of bacterial cell walls by penetrating the cell wall and reaching its target, the penicillin-binding protein, to ultimately produce antibacterial effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coly Mycin M Injectable Product
Description: Coly Mycin M is the originally marketed colistimethate sodium for injection.
Study: NCT05886647

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham compatorator and inspiratory muscle training
Description: As for the patients allocated in the control group, they will receive the HD-tDCS sham for 20 minutes associated with IMT, following for the same training, duration and load increment used in the experimental group.
Study: NCT04512742

Intervention type: OTHER
Group type: OTHER
Intervention: biting by Phlebotomus duboscqi infected with Leishmania major
Description: The first six subjects will be exposed to biting by Phlebotomus duboscqi infected by Leishmania major and assess the 'take rate', that is the number of subjects developing parasitologically confirmed cutaneous leishmaniasis (PCCL) lesions. If 6/6 subjects develop PCCL lesions no further recruitment will take place; if only \< 6 subjects develop PCCL lesions, then an adaptive design will be followed.
Study: NCT06308978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FT819
Description: FT819 will be administered as a single-dose intravenous (IV) infusion at planned dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered as an IV infusion at planned dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as an IV infusion at planned dose levels.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered as an IV infusion at planned dose levels.
Study: NCT06128863

Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab, Eftilagimod alpha
Description: Eftilagimod alpha 20 mg s.c. every 2 weeks (5 doses), Pembrolizumab 200 mg i.v. every 3 weeks (3 cycles), Radiotherapy 50 Gy (25 x 2 Gy)
Study: NCT05117840

Intervention type: DEVICE
Intervention: Low-dose CT scan
Description: Standard of care screening for individuals at high-risk of lung cancer
Study: NCT04818320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Day 1: 1800mg BD, day 2-5: 800mg BD
Study: NCT05359159

Intervention type: OTHER
Intervention: Data collection
Description: Data collection

Intervention type: OTHER
Intervention: Data collection
Description: Data collection
Study: NCT05880693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Group 1 received dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Description: the group 2 received magnesium sulfate
Study: NCT06394336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle strengthening
Description: Strengthening exercises for the intrinsic muscles of the foot and hips

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment (oral analgesic/anti-inflammatory drug)
Description: oral analgesic/anti-inflammatory drug. Education.
Study: NCT04472429

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: carboplatin will be administered intravenous on Day 1 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: carboplatin will be administered intravenous on Day 1 of each 28 day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paclitaxel
Description: paclitaxel will be administered intravenous on Days 1,8, and 15 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: paclitaxel will be administered intravenous on Days 1,8, and 15 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: retifanlimab will be administered intravenous on Day 1 of each 28 day cycle
Study: NCT06053593

Intervention type: DEVICE
Intervention: Testing of self collected urine
Description: Each PWD will test their self-collected urine.

Intervention type: DEVICE
Intervention: Testing of self collected urine
Description: Each PWD will test their self-collected urine.

Intervention type: DEVICE
Intervention: Labeling Evaluation
Description: Each PWD will complete a labeling evaluation.

Intervention type: DEVICE
Intervention: Labeling Evaluation
Description: Each PWD will complete a labeling evaluation.

Intervention type: DEVICE
Intervention: Urine Control testing
Description: Each PWD will test four urine control solutions.

Intervention type: DEVICE
Intervention: Urine Control testing
Description: Each PWD will test four urine control solutions.
Study: NCT05457842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pudexacianinium chloride
Description: Intradermal injection
Study: NCT04971694

Intervention type: OTHER
Intervention: No interventions or procedures
Description: This is a retrospective observational study and data will be collected from the subject's existing medical record. No interventions or procedures will be required for this study.
Study: NCT05035212

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF
Description: RSV vaccine (RSVpreF)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF
Description: RSV vaccine (RSVpreF)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF
Description: RSV vaccine (RSVpreF)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF
Description: RSV vaccine (RSVpreF)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSVpreF
Description: RSV vaccine (RSVpreF)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06264180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vusolimogene Oderparepvec
Description: Genetically modified Herpes Simplex Type 1 Virus.
Study: NCT05935267

Intervention type: PROCEDURE
Intervention: thoracic irrigation
Description: We will start this study using 20% as the approximate national intervention rate, based on current literature, with the goal of detecting a 50% reduction in the experimental arm (i.e. 10% secondary intervention rate after thoracic irrigation). Therefore, we will plan to enroll 108 patients in the irrigation cohort and 324 patients in the control cohort. An interim analysis will be conducted once 54 patients have been enrolled in the irrigation cohort. The secondary intervention rate in the irrigation cohort and the standard cohort will be determined, and any adjustments to sample size will be made at that time.

Intervention type: PROCEDURE
Intervention: thoracic irrigation
Description: We will start this study using 20% as the approximate national intervention rate, based on current literature, with the goal of detecting a 50% reduction in the experimental arm (i.e. 10% secondary intervention rate after thoracic irrigation). Therefore, we will plan to enroll 108 patients in the irrigation cohort and 324 patients in the control cohort. An interim analysis will be conducted once 54 patients have been enrolled in the irrigation cohort. The secondary intervention rate in the irrigation cohort and the standard cohort will be determined, and any adjustments to sample size will be made at that time.

Intervention type: PROCEDURE
Intervention: thoracic irrigation
Description: We will start this study using 20% as the approximate national intervention rate, based on current literature, with the goal of detecting a 50% reduction in the experimental arm (i.e. 10% secondary intervention rate after thoracic irrigation). Therefore, we will plan to enroll 108 patients in the irrigation cohort and 324 patients in the control cohort. An interim analysis will be conducted once 54 patients have been enrolled in the irrigation cohort. The secondary intervention rate in the irrigation cohort and the standard cohort will be determined, and any adjustments to sample size will be made at that time.
Study: NCT06247098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus Lift augmentation
Description: Randomised Sinus Lift augmentation either with Xenograft - Autogenous ratio 1:4 (test) or Xenograft alone (Control)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus Lift augmentation
Description: Randomised Sinus Lift augmentation either with Xenograft - Autogenous ratio 1:4 (test) or Xenograft alone (Control)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cone-beam computed tomography systems (CBCT)
Description: An research only use of CBCT at visit 2 to review healing status.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cone-beam computed tomography systems (CBCT)
Description: An research only use of CBCT at visit 2 to review healing status.
Study: NCT04965493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venetoclax
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Intravenous (IV)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Intravenous (IV)
Study: NCT05398653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIL62
Description: An intravenous (IV) infusion of 600 mg of MIL62 will be administered at Week 1，Week 3.If the treatment is effective, MIL62 will continue be administered at W25，W27.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Participants will receive Cyclosporine at a starting oral dose 3.5 mg/kg/d, divided into 2 doses, try to give every 12 hours.The dose was adjusted according to the blood concentration of cyclosporine monitored every 2 weeks ±3 days until the target blood concentration of 125\~175 ng/ mL was reached.Cyclophosphamide will be maintained for 12 months, after which the dose was reduced by about 1/3 to 1/2 of the original dose each month, and discontinued after 2 months.
Study: NCT04785287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CTLA4 Monoclonal Antibody BMS-986218
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CTLA4 Monoclonal Antibody BMS-986218
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT06264180

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Anti-PD-1 Monoclonal Antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Anti-PD-1 Monoclonal Antibody

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab + Relatlimab
Description: Nivolumab: Anti-PD-1 Monoclonal antibody. Relatlimab: A lymphocyte activation gene-3 (LAG-3) blocking antibody.
Study: NCT05963269

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computer assisted intramuscular learning game
Description: It is an educational game that can only be opened from the computer, with questions and answers and cases. The game is currently under development by the developers. The researcher will be able to see how many times the students entered the game and how many points they got.
Study: NCT04785287

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT06298032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olamkicept Part A
Description: Intravenous infusion. Single dose.~Part A consists of 3 different doses~* 1200 mg~* 1800 mg~* 2400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olamkicept Part B
Description: Intravenous infusion. Multiple doses.~Part B consists of 3 different doses.~* 1200 mg~* 1800 mg~* 2400 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion
Study: NCT06345872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: Includes 8 weekly sessions of CBT-I and 2 bi-monthly boosters. Each session is to be completed individually by the participant in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual
Description: Includes 8 weekly sessions of standard treatment and 2 bi-monthly boosters. Each session is to be completed individually by the participant in a single sitting (less than 45 mins). Each session should be completed in 7 days with next session released only after prior one completed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tapered Withdrawal
Description: Individualized gradual tapered withdrawal following CDC guidelines, additional check-ins and motivational interviewing with a therapist.

Intervention type: OTHER
Group type: OTHER
Intervention: Tapered Withdrawal
Description: Individualized gradual tapered withdrawal following CDC guidelines, additional check-ins and motivational interviewing with a therapist.
Study: NCT06431022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: webSTAIR
Description: WebSTAIR is a self-paced, brief skills-focused treatment for PTSD that focused on improving one's ability to manage emotions and relationships.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: webSTAIR
Description: WebSTAIR is a self-paced, brief skills-focused treatment for PTSD that focused on improving one's ability to manage emotions and relationships.
Study: NCT06264180

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: A programmed death receptor-1 (PD-1)-blocking antibody indicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single-agent chemotherapy
Description: Dacarbazine, temozolomide, or paclitaxel/albumin-bound paclitaxel.
Study: NCT05511662

Intervention type: OTHER
Intervention: PRO follow up
Description: On the basis of the routine follow-up group, interactive follow-up was conducted through the chronic disease follow-up system, including the APP for regular follow-up (bound to sign the informed consent form, and the account of the patient and his immediate family who can be familiar with the WeChat applet), SMS reminders, and doctors when necessary. Wechat/platform communication and exchange, inappropriate ECG data upload and other multi-dimensional follow-up, at the same time assisting the ECG integrated follow-up platform for ECG data management and medication guidance
Study: NCT06103760

Intervention type: DRUG
Group type: OTHER
Intervention: Esketamine Nasal Spray [Spravato]
Description: This is an uncontrolled, single arm, naturalistic study. There will be three treatment phases: Phase 1 - Acute treatment phase (weeks 1-4); Phase 2 - Maintenance treatment phase (weeks 5-8); Phase 3 - Continuation treatment phase (Weeks 9-25). Phase 1 is the critical component of our study as it determines our primary outcomes.
Study: NCT05079230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magrolimab
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablets administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Venetoclax
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered according to region-specific drug labeling, either subcutaneously (SC) or intravenously (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine
Description: Administered according to region-specific drug labeling, either subcutaneously (SC) or intravenously (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magrolimab Placebo
Description: Administered intravenously (IV)
Study: NCT06374654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Exercise Protocol
Description: The home-based eccentric exercise protocol is a do-as-tolerated variation on the protocol described by Alfredson et al. in 1998. The protocol includes doing a series of heel raises, twice daily. No equipment is necessary. Patients will be given handouts and video links that depict and describe the exercises and their prescribed frequency.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formal Physical Therapy
Description: Patients will be given a prescription for physical therapy consisting of 1-2 sessions per week for 6 weeks, with a renewal for another 6 weeks to be executed at the physical therapists' discretion. If an in-person visit is necessary for the renewal, or is requested by the physical therapist, the patient will be seen again in the office. Each patient will be given a release form to provide to his or her physical therapist. The release form will request a written record of all the treatment methods used by the physical therapist. Physical therapists who participate in the care of patients in this study will treat each patient using any and all methods that their professional experience deems clinically necessary.
Study: NCT05358808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCB008
Description: TCB008 is derived from the peripheral blood mononuclear cells (PBMCs) of unrelated, healthy donors and consists of expanded cluster designation (CD)3+ T cells expressing the γ chain variable region 9 δ-chain variable region 2 (Vγ9Vδ2) T cell receptor (TCR); it is infused into patients to boost their immune system. It is currently developed for treatment of cancers and infectious diseases.
Study: NCT06431022

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHW coaching
Description: CHWs will provide webSTAIR coaching, which includes motivational, problem solving, and cognitive-behavioral strategies to enhance skills practice and engagement.
Study: NCT05256303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Hospital care
Description: Patients receive hospital-level care in their home

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Hospital care
Description: Patients receive hospital-level care in the hospital.
Study: NCT06534164

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full/High Tech Telerehabilitation decision support system
Description: The TeleRehaB DSS intervention includes HOLOBalance balance rehabilitation programme delivered via an augmented reality hologram of a virtual physiotherapist. The system delivers exercises demonstrated via a hologram of the physiotherapist and corrected in real time by the hologram prompts based on performance monitoring via sensors. It includes different multisensory balance and gait exercises, physical activity and memory training and exergames (video games which are also exercises) to improve balance function in older adults. The system can thus assess and remotely monitor how users are performing the exercises.~Exercise progressions will be suggested by the AI-supported TeleRehaB DSS and approved by the clinicians, which will be loaded into the participant's programme.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Basic/Low Tech Telerehabilitation decision support system
Description: The basic system does not inlcude exergames, a smartwatch, or a mobile phone for activity tracking.~It includes different multisensory balance and gait exercise, cognitive training and real-time feedback from motion sensors.~Exercise progressions will be suggested by the AI-supported TeleRehaB DSS and approved by the clinicians, which will be loaded into the participant's programme.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OTAGO Home exercise program
Description: balance rehabilitation program

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vestibular rehabilitation program
Description: vestibular rehabilitation and dizziness program
Study: NCT05513170

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Use of Densah Burs in closed sinus lift
Description: Closed sinus will be performed using Densah Burs. Densah Burs enhance bone quality through osseodensification; a process through which bone is compacted and auto-graphted in the marrow spaces and apically to elevate the sinus floor and enhance bone density.
Study: NCT05093686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RUBIES
Description: RUBIES is an 8 module intervention that begins with foundational education on ASD (Session1), followed by introducing basic applied behavior analysis principles (Session 2). Instruction is then provided on strategies that can prevent problematic behaviors from occurring (Session 3 and 4). Reinforcement (Session 5) reviews the use of tangible and social reinforcers tools to promote new/desired behaviors while planned ignoring and functional communication training (Session 6) teaches that disruptive behavior can serve as a form of communication while ignoring disruptive communicative attempts. Sessions conclude with instruction on effective ways to deliver commands to promote compliance (Session 7) and targeting approaches to ensure positive behavior gains can maintain over time and strategies can be used across classrooms and staff (Session 8).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Training
Description: Usual Care Training is an 8 module psychoeducation program that will provide foundational information on autism spectrum disorders, including the diagnostic criteria, appropriate educational services, common interventions, and how to promote social skills in the classroom.
Study: NCT04926701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETD001 single dose
Description: Single ascending doses of inhaled ETD001